"Fibroblast" pharmacotherapy - Advancing the next generation of therapeutics for clinical cardiology

Journal of Molecular and Cellular Cardiology

Volumn 94, Issue , 2016, Pages 176-179

  Eadie, Ashley L ^a   Simpson, Jeremy A ^b   Brunt, Keith R ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

Angiotensin; Autophagy; Chymase; Extracellular matrix; Fibrosis; Heart failure

Indexed keywords

CHYMASE; ANGIOTENSIN II;

AUTOPHAGY; AUTOREGULATION; BLOOD PRESSURE REGULATION; CELL FUNCTION; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; HEART FIBROBLAST; HUMAN; MAST CELL DEGRANULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; FIBROBLAST; HEART FAILURE;

ANGIOTENSIN II; CHYMASES; FIBROBLASTS; HEART FAILURE; HUMANS;

EID: 84963526820     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2016.03.018     Document Type: Editorial

References (51)

1. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007, 8:221-233.
2. Ott H.C., Matthiesen T.S., Goh S.K., Black L.D., Kren S.M., Netoff T.I., et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 2008, 14:213-221.
3. Guyette J.P., Charest J.M., Mills R.W., Jank B.J., Moser P.T., Gilpin S.E., et al. Bioengineering human myocardium on native extracellular matrix. Circ. Res. 2016, 118:56-72.
4. Souders C.A., Bowers S.L., Baudino T.A. Cardiac fibroblast: the renaissance cell. Circ. Res. 2009, 105:1164-1176.
5. Hutchison N., Fligny C., Duffield J.S. Resident mesenchymal cells and fibrosis. Biochim. Biophys. Acta 1832, 2013:962-971.
6. Francis Stuart S.D., De Jesus N.M., Lindsey M.L., Ripplinger C.M. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J. Mol. Cell. Cardiol. 2016, 91:114-122.
7. Ma Y., Halade G.V., Lindsey M.L. Extracellular matrix and fibroblast communication following myocardial infarction. J. Cardiovasc. Transl. Res. 2012, 5:848-857.
8. Kong P., Christia P., Frangogiannis N.G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 2014, 71:549-574.
9. Dostal D., Glaser S., Baudino T.A. Cardiac fibroblast physiology and pathology. Compr. Physiol. 2015, 5:887-909.
10. Weber K.T., Sun Y., Bhattacharya S.K., Ahokas R.A., Gerling I.C. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 2013, 10:15-26.
11. Chung C.S., Hutchinson K.R., Methawasin M., Saripalli C., Smith J.E., Hidalgo C.G., et al. Shortening of the elastic tandem immunoglobulin segment of titin leads to diastolic dysfunction. Circulation 2013, 128:19-28.
12. Lamberts R.R., Willemsen M.J., Perez N.G., Sipkema P., Westerhof N. Acute and specific collagen type I degradation increases diastolic and developed tension in perfused rat papillary muscle. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H889-H894.
13. Karnik S.S., Unal H., Kemp J.R., Tirupula K.C., Eguchi S., Vanderheyden P.M., et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological angiotensinergic stimuli [corrected]. Pharmacol. Rev. 2015, 67:754-819.
14. Palmer S.C., Mavridis D., Navarese E., Craig J.C., Tonelli M., Salanti G., et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet (London, England) 2015, 385:2047-2056.
15. Simpson J., Jhund P.S., Silva Cardoso J., Martinez F., Mosterd A., Ramires F., et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J. Am. Coll. Cardiol. 2015, 66:2059-2071.
16. Li E.C., Heran B.S., Wright J.M. Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst. Rev. 2014, 8.
17. Wei C.C., Hase N., Inoue Y., Bradley E.W., Yahiro E., Li M., et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J. Clin. Investig. 2010, 120:1229-1239.
18. De Campo B.A., Goldie R.G., Jeng A.Y., Henry P.J. Role of endothelin-converting enzyme, chymase and neutral endopeptidase in the processing of big ET-1, ET-1(1-21) and ET-1(1-31) in the trachea of allergic mice. Clin. Sci. (Lond. Engl.: 1979) 2002, 103(Suppl. 48):353s-356s.
19. Siragy H.M., Howell N.L., Ragsdale N.V., Carey R.M. Renal interstitial fluid angiotensin. Modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension 1995, 25:1021-1024.
20. McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014, 371:993-1004.
21. Mital S., Chung W.K., Colan S.D., Sleeper L.A., Manlhiot C., Arrington C.B., et al. Renin-angiotensin-aldosterone genotype influences ventricular remodeling in infants with single ventricle. Circulation 2011, 123:2353-2362.
22. Sakata Y., Shiba N., Takahashi J., Miyata S., Nochioka K., Miura M., et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur. Heart J. 2015, 36:915-923.
23. Wright J.T., Williamson J.D., Whelton P.K., Snyder J.K., Sink K.M., Rocco M.V., et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med. 2015, 373:2103-2116.
24. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:931-936.
25. Zou Y., Akazawa H., Qin Y., Sano M., Takano H., Minamino T., et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol. 2004, 6:499-506.
26. Yasuda N., Akazawa H., Ito K., Shimizu I., Kudo-Sakamoto Y., Yabumoto C., et al. Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice. Hypertension 2012, 59:627-633.
27. Mederos y Schnitzler M., Storch U., Gudermann T. AT1 receptors as mechanosensors. Curr. Opin. Pharmacol. 2011, 11:112-116.
28. Martino T.A., Tata N., Simpson J.A., Vanderlaan R., Dawood F., Kabir M.G., et al. The primary benefits of angiotensin-converting enzyme inhibition on cardiac remodeling occur during sleep time in murine pressure overload hypertrophy. J. Am. Coll. Cardiol. 2011, 57:2020-2028.
29. Fu L., Wei C.C., Powell P.C., Bradley W.E., Ahmad S., Ferrario C.M., et al. Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. J. Mol. Cell. Cardiol. 2016, 92:1-9.
30. Zablocki D., Sadoshima J. The one-two punch: knocking out angiotensin II in the heart. J. Clin. Investig. 2010, 120:1028-1031.
31. Ferrario C.M., Ahmad S., Nagata S., Simington S.W., Varagic J., Kon N., et al. An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin. Sci. (Lond. Engl.: 1979) 2014, 126:461-469.
32. Ahmad S., Wei C.C., Tallaj J., Dell'Italia L.J., Moniwa N., Varagic J., et al. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J. Am. Soc. Hypertens. 2013, 7:128-136.
33. Seqqat R., Guo X., Rafiq K., Kolpakov M.A., Guo J., Koch W.J., et al. Beta1-adrenergic receptors promote focal adhesion signaling downregulation and myocyte apoptosis in acute volume overload. J. Mol. Cell. Cardiol. 2012, 53:240-249.
34. Fu L., Wei C.C., Powell P.C., Bradley W.E., Collawn J.F., Dell'Italia L.J. Volume overload induces autophagic degradation of procollagen in cardiac fibroblasts. J. Mol. Cell. Cardiol. 2015, 89:241-250.
35. Ghavami S., Cunnington R.H., Gupta S., Yeganeh B., Filomeno K.L., Freed D.H., et al. Autophagy is a regulator of TGF-beta1-induced fibrogenesis in primary human atrial myofibroblasts. Cell Death Dis. 2015, 6.
36. Peschke K., Dudeck A., Rabenhorst A., Hartmann K., Roers A. Cre/loxP-based mouse models of mast cell deficiency and mast cell-specific gene inactivation. Methods Mol. Biol. (Clifton, NJ) 2015, 1220:403-421.
37. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 1990, 66:883-890.
38. Oyamada S., Bianchi C., Takai S., Chu L.M., Sellke F.W. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion. J. Pharmacol. Exp. Ther. 2011, 339:143-151.
39. Zheng J., Wei C.C., Hase N., Shi K., Killingsworth C.R., Litovsky S.H., et al. Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog. PLoS One 2014, 9.
40. Matsumoto T., Wada A., Tsutamoto T., Ohnishi M., Isono T., Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation 2003, 107:2555-2558.
41. Roszkowska-Chojecka M.M., Walkowska A., Gawrys O., Baranowska I., Kalisz M., Litwiniuk A., et al. Effects of chymostatin, a chymase inhibitor, on blood pressure, plasma and tissue angiotensin II, renal haemodynamics and renal excretion in two models of hypertension in the rat. Exp. Physiol. 2015, 100:1093-1105.
42. Takai S., Jin D. Improvement of cardiovascular remodelling by chymase inhibitor. Clin. Exp. Pharmacol. Physiol. 2016, 43:387-393.
43. Takai S., Jin D., Chen H., Li W., Yamamoto H., Yamanishi K., et al. Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats. J. Hypertens. 2014, 32:1637-1648. (discussion 49).
44. Pernow J., Kaijser L., Lundberg J.M., Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996, 94:2077-2082.
45. Lin J., Davis H.B., Dai Q., Chou Y.M., Craig T., Hinojosa-Laborde C., et al. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens. Res. 2008, 31:1225-1231.
46. Tchougounova E., Pejler G. Regulation of extravascular coagulation and fibrinolysis by heparin-dependent mast cell chymase. FASEB J. 2001, 15:2763-2765.
47. Janicki J.S., Spinale F.G., Levick S.P. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. - Eur. J. Physiol. 2013, 465:687-697.
48. Li J., Jubair S., Janicki J.S. Estrogen inhibits mast cell chymase release to prevent pressure overload-induced adverse cardiac remodeling. Hypertension 2015, 65:328-334.
49. Wang H., Jessup J.A., Zhao Z., Da Silva J., Lin M., MacNamara L.M., et al. Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. PLoS One 2013, 8.
50. Kumar R., Thomas C.M., Yong Q.C., Chen W., Baker K.M. The intracrine renin-angiotensin system. Clin. Sci. (Lond. Engl.: 1979) 2012, 123:273-284.
51. Bayer A single-blind pilot study to investigate safety and tolerability of the chymase inhibitor bay1142524 in clinically stable patients with left-ventricular dysfunction. ClinicalTrials.gov (Internet) 2015, National Library of Medicine (US), Bethesda (MD), -(cited 2016 Apr 6). Available from: https://clinicaltrials.gov/ct2/show/NCT02452515. NLM Identifier: NCT02452515.